| Literature DB >> 35769668 |
Muhammad Tahir Aleem1, Asad Khan1, Zhaohai Wen1, Zhengqing Yu1, Kun Li1,2, Aftab Shaukat3, Cheng Chen1, Tauseef-Ur -Rehman4, Mingmin Lu1, Lixin Xu1, Xiaokai Song1, Xiangrui Li1, Ruofeng Yan1.
Abstract
Background. Trichinellosis is a foodborne zoonotic disease caused by Trichinella spp., including Trichinella spiralis. This parasitic disease ranks as seven of the most infectious in the world. In this context, it is important to develop a vaccine that can combat Trichinellosis, especially for humans and pigs. This would be an important step in preventing transmission. In this study, we focus on homology modelling, binding site prediction, molecular modelling, and simulation techniques used to explore the association between Trichinella spiralis membrane-associated progesterone receptor component 2 (Ts-MAPRC2) and the human PGRMC1 protein. It was found that the progesterone receptor component 2 of T. spiralis has 44.54% sequence identity with human PGRMC1 (PDB ID: 4X8Y). Binding sites predicted for human PGRMC1 are GLU 7, PHE 8, PHE 10, PHE 18, LEU 27, ASP 36, and VAL 104. Molecular docking has six clusters based on Z scores. They range from -1.5 to 1.8. It was found that the progesterone receptor component 2 of T. spiralis has 44.54% sequence identity with human PGRMC1. During simulation, the average RMSD was 2.44 ± 0.20 Å, which indicated the overall stability of the protein. Based on docking studies and computational simulations, we hypothesized that the interaction of the proteins Trichinella spiralis membrane-associated progesterone receptor component 2 and human PGRMC1 formed stable complexes. The discovery of Ts-MAPRC2 may pave the way for the development of drugs and vaccines to treat Trichinellosis.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35769668 PMCID: PMC9236782 DOI: 10.1155/2022/7414198
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1(a) Ramachandran plot. The residues in the red area are lying in the most favorable region (92.1%), while 6.9% of residues lie in additional allowed regions (yellow region). There was no residue in the disallowed region (white area). (b) ERRAT quality chart.
Figure 2Predicted binding sites of human PGRMC1 shown in magenta sticks.
HADDOCK clusters of target protein and human PGRMC1 protein.
| Clusters | Haddock score | Size | RMSD | Van der Waals energy | Electrostatic energy | Desolvation energy | Restraint's violation energy | Buried surface area |
|
|---|---|---|---|---|---|---|---|---|---|
| 4 | −49.8 ± 12.3 | 11 | 1.1 ± 0.9 | −66.6 ± 3.0 | −492.9 ± 57.0 | −4.0 ± 1.6 | 1194.0 ± 81.8 | 2592.6 ± 165.3 | -2.2 |
| 2 | −19.1 ± 8.6 | 16 | 9.3 ± 0.1 | −60.6 ± 6.6 | −386.4 ± 20.9 | 2.5 ± 4.6 | 1162.5 ± 47.2 | 2317.2 ± 132.8 | -0.7 |
| 9 | −16.4 ± 18.1 | 6 | 13.4 ± 0.1 | −65.6 ± 5.5 | −224.1 ± 16.8 | −21.5 ± 3.7 | 1155.6 ± 122.8 | 2005.8 ± 95.4 | -0.6 |
| 15 | −14.1 ± 19.3 | 4 | 11.8 ± 0.2 | −54.5 ± 10.1 | −348.1 ± 18.6 | −14.0 ± 1.7 | 1240.1 ± 179.0 | 2317.9 ± 285.9 | -0.5 |
| 1 | −5.6 ± 10.0 | 26 | 14.9 ± 0.0 | −62.2 ± 1.8 | −180.4 ± 31.1 | −18.3 ± 1.2 | 1109.5 ± 118.6 | 1866.2 ± 19.6 | -0.1 |
| 8 | 0.6 ± 9.4 | 7 | 11.5 ± 0.1 | −56.2 ± 5.1 | −209.2 ± 34.9 | −14.0 ± 2.7 | 1125.9 ± 101.5 | 1919.1 ± 41.5 | 0.2 |
Figure 3Target protein and human PGRMC1 protein cluster 4. The blue surface shows the human PGRMC1 protein while the red surface shows the target protein.
Protein-protein interactions based on KFC.
| Chain | Residue | Number | KFC configuration value |
|---|---|---|---|
| A | PHE | 8 | HS (0.90 and 0.29) |
| A | PRO | 24 | HS (0.47) |
| A | ARG | 25 | HS (0.27) |
| A | ILE | 26 | HS (0.84 and 0.29) |
| A | ASP | 36 | HS (0.52) |
| A | THR | 38 | HS (1.18) |
| A | LYS | 39 | HS (1.20 and 0.28) |
| A | ARG | 41 | HS (1.38 and 0.28) |
| A | LYS | 42 | HS (0.24) |
| A | THR | 98 | HS (0.14) |
| A | HIS | 102 | HS (1.68 and 0.19) |
| A | VAL | 104 | HS (0.31) |
| B | ASN | 125 | HS (0.65) |
| B | ASP | 127 | HS (0.54) |
| B | LEU | 173 | HS (1.21 and 0.24) |
| B | ALA | 174 | HS (0.05) |
| B | LEU | 176 | HS (0.49 and 0.14) |
| B | ILE | 181 | HS (1.17 and 0.17) |
| B | LEU | 184 | HS (0.96 and 0.25) |
| B | ARG | 185 | HS (1.60 and 0.35) |
| B | MET | 189 | HS (1.23 and 0.21) |
| B | LYS | 205 | HS (1.64 and 0.37) |
| B | LEU | 206 | HS (0.47 and 0.23) |
| B | ASP | 211 | HS (0.19) |
Figure 4Protein-protein complex stability analysis by MD simulation. (a) RMSD plots. (b) RMSF plots. (c) Rg plots.
Figure 5The dynamic motions analysis by simulation. (a) Cross-correlation map of human PGRMC1. (b) Cross-correlation map of the target protein. (c) PCA plot of Human PGRMC1. (d) PCA plot of the target protein.